Industry News — Clinical Updates

Ophthotech Initiates First Expansion Study to Further Evaluate Fovista for Treating Wet AMD

Ophthotech Corporation (New York, NY) has initiated the first of several planned expansion trials to investigate the potential role of Fovista (anti-platelet derived growth factor, anti-PDGF) combination therapy in reducing subretinal fibrosis, addressing suboptimal treatment response, and reducing treatment burden in wet-AMD patients receiving anti-VEGF monotherapy. The first expansion trial is a phase 2a open-label study investigating the potential role of anti-PDGF therapy in combination with anti-VEGF therapy in reducing subretinal fibrosis in wet-AMD patients.

The anti-PDGF phase 3 program consists of 3 clinical trials to evaluate the safety and efficacy of anti-PDGF for use in combination with anti-VEGF agents for the treatment of wet AMD. Ophthotech expects to enroll up to 1866 patients in the 3 trials in more than 225 centers worldwide and to have initial, topline data from the phase 3 clinical trial available in 2016.

Updated August 5, 2014